Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aviptadil
- Development stage
- Phase 3
- Lead developer
- NRx Pharmaceuticals
- Modality
- Small Molecules, Peptides
- Administration
- Inhalation, Intravenous, Intracavernosal
01
Overview
Aviptadil is a synthetic form of human vasoactive intestinal polypeptide (VIP), which was discovered in 1970. It has potential anti-cytokine, anti-inflammatory, and immune-regulatory activities. VIP is highly localized in the lungs (70%) and binds with alveolar type II (AT II) cells via VPAC1 receptors. Aviptadil has been investigated for various inflammatory conditions, including acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), and most recently for COVID-19 respiratory failure. In COVID-19 treatment, aviptadil works by upregulating surfactant production, inhibiting cytokine synthesis, preventing cytopathy, and blocking replication of the SARS-CoV-2 virus in pulmonary cells.
- Brand names
- ZyesamiInvicorp
- Other names
- Vasoactive intestinal octacosapeptidePorcine vasoactive intestinal octacosapeptide
02
Targets
VIPR1 (Vasoactive intestinal peptide receptor 1)VIPR2 (Vasoactive intestinal polypeptide receptor 2)
Beyond the preview
Go deeper on aviptadil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aviptadil.